

ORIGINAL ARTICLE

Cellular and viral peptides bind multiple sites on the N-terminal domain of clathrin

Julia Muenzner¹ | Linton M. Traub² | Bernard T. Kelly³ | Stephen C. Graham¹

¹Department of Pathology, University of Cambridge, Cambridge, UK

²Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA

³Cambridge Institute for Medical Research, Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK

Corresponding Authors: Bernard T. Kelly, Cambridge Institute for Medical Research, Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK (btk1000@cam.ac.uk) and

Stephen C. Graham, Department of Pathology, University of Cambridge, Cambridge, UK (scg34@cam.ac.uk).

Funding information

EU FP7 infrastructure grant BIOSTRUCT-X, Grant/Award number: 283570; Sir Henry Dale Fellowship; Royal Society; Wellcome Trust, Grant/Award number: 098406/Z/12/Z; NIH R01, Grant/Award number: GM106963; Wellcome grant, Grant/Award number: 090909/Z/09/Z; Wellcome Trust Strategic Award, Grant/Award number: 079895.

Short peptide motifs in unstructured regions of clathrin-adaptor proteins recruit clathrin to membranes to facilitate post-Golgi membrane transport. Three consensus clathrin-binding peptide sequences have been identified and structural studies show that each binds distinct sites on the clathrin heavy chain N-terminal domain (NTD). A fourth binding site for adaptors on NTD has been functionally identified but not structurally characterised. We have solved high resolution structures of NTD bound to peptide motifs from the cellular clathrin adaptors β 2 adaptin and amphiphysin plus a putative viral clathrin adaptor, hepatitis D virus large antigen (HDAg-L). Surprisingly, with each peptide we observe simultaneous peptide binding at multiple sites on NTD and viral peptides binding to the same sites as cellular peptides. Peptides containing clathrin-box motifs (CBMs) with the consensus sequence $L\Phi x\Phi[DE]$ bind at the 'arrestin box' on NTD, between β -propeller blades 4 and 5, which had previously been thought to bind a distinct consensus sequence. Further, we structurally define the fourth peptide binding site on NTD, which we term the Royle box. In vitro binding assays show that clathrin is more readily captured by cellular CBMs than by HDAg-L, and site-directed mutagenesis confirms that multiple binding sites on NTD contribute to efficient capture by CBM peptides.

KEYWORDS

amphiphysin, arrestin, assembly polypeptide 2 (AP2), clathrin-mediated endocytosis, endocytosis, hepatitis D virus

1 | INTRODUCTION

Clathrin mediates vesicular transport between post-Golgi membranes in eukaryotes and is targeted to specific membranes by interactions with clathrin adaptor proteins.^{1–3} Individually these interactions are weak,⁴ but because clathrin polymerization drives the growth of a network of available binding sites, a wide range of adaptors and accessory factors may be recruited and retained at sites of coated pit formation.^{2,5–7}

Clathrin:adaptor interactions are typically driven by linear peptide motifs in the unstructured regions of clathrin adaptors that bind the N-terminal β -propeller domain (NTD) of the clathrin heavy chain at several distinct sites (reviewed in reference 8): the "clathrin-box motif" (CBM), consensus sequence $L\Phi x\Phi[DE]$ (where x denotes any amino acid, Φ denotes a bulky hydrophobic residue and [DE] is a glutamate

or aspartate), binds in a groove between blades 1 and 2 of the NTD β -propeller^{3,9,10}; and the "W box" consensus $PWxxW$, binds the cleft near the centre of the NTD β -propeller.^{11,12} Thirdly, an extended surface loop of the arrestin 2 long isoform (arrestin2L) has been shown to occupy the "arrestin box", a site lying between blades 4 and 5 of the NTD that binds peptides with consensus $[LI][LI]GxL$.¹³ More recently, a fourth adaptor binding site on the clathrin NTD, between blades 6 and 7, was defined by Willox and Royle¹⁴ on the basis of functional experiments in HeLa cells expressing clathrin heavy chain mutated in the NTD. This last study found that even a single functional NTD site was sufficient to sustain transferrin uptake.

The observation that any individual binding site on NTD is sufficient to sustain clathrin-mediated endocytosis of the transferrin receptor raises several questions. Does it reflect promiscuity in the binding of clathrin-interaction motifs, such that an individual

clathrin-binding motif can bind to different sites on NTD, or does it instead suggest intrinsic redundancy in the recruitment of adaptors such that endocytosis still proceeds even when an entire 'class' of clathrin-binding motif is prevented from binding clathrin? Previous studies suggest the latter, as each peptide binding site on clathrin characterized to date has a distinct consensus binding motif.^{10,12,13} However, recent studies have suggested that the binding of peptides to clathrin may be promiscuous.^{14,15} Promiscuity of CBM peptides for multiple sites on clathrin is relevant in the context of host: pathogen interactions, as it has previously been observed that viruses contain motifs resembling cellular CBMs that interact with clathrin in cells. These viral proteins have the ability to sequester clathrin, thus preventing endocytosis.^{16,17} In the case of hepatitis D virus (HDV), which harbours a putative CBM sequence in the C-terminal region of the large antigen protein (HDAg-L), the presence of the clathrin binding motif seems essential for production of virus particles.¹⁸ If viral CBM peptides bind only to the clathrin box on NTD it would be possible to blockade this site using a small molecule inhibitor.¹⁹ This blockade would prevent virus hijacking of clathrin without perturbing cellular endocytosis, which can proceed when binding to the NTD "clathrin box" site is disrupted.¹⁴ However, if viral CBMs bind multiple sites on NTD with comparable affinities then small molecule interventions are unlikely to succeed. We thus sought to investigate the relative affinity of cellular vs viral peptides for clathrin NTD and to compare their modes of binding. Further, we sought to investigate the potential degeneracy of clathrin binding that had been suggested by previous studies.^{14,15}

Here we present high-resolution structures of clathrin NTD bound to cellular and viral peptide motifs. Surprisingly, in all cases we observe peptide binding at multiple sites on NTD. We use clathrin-binding assays and site-directed mutagenesis to qualitatively assess the binding of these peptide motifs to the different sites on NTD. Further, we provide the first structural characterization of the putative "fourth" adaptor binding site on clathrin NTD.

2 | RESULTS

2.1 | Cellular clathrin-binding motifs recruit clathrin more efficiently than those from hepatitis D virus

The CBMs from the cellular proteins $\beta 2$ adaptin (AP2CBM) and amphiphysin (AmphCBM),^{9,20} the W box motif of amphiphysin (Wbox),^{11,12,20,21} and the C-terminal extensions of HDAg-L from 2 different HDV genotypes containing putative clathrin binding motifs (HDAg-L1 and HDAg-L2, respectively)^{16,18} were fused to glutathione S-transferase (GST) (Figure 1A) and immobilized on glutathione resin for use in "GST pull-down" experiments to capture clathrin purified from pig brain. In addition, to aid comparison with previous biochemical studies,¹¹ an extended amphiphysin CBM construct (termed Amph4T1) was used in which the clathrin-binding motif is followed by the amino acids "LERPHRD" arising from the XhoI cloning site and subsequent vector-derived nucleotides.²² Consistent with previous studies,^{11,12} clathrin was efficiently captured by GST fused to AP2CBM, AmphCBM, Amph4T1 or the amphiphysin Wbox, while it




FIGURE 1 Cellular and viral peptide motifs bind clathrin N-terminal domain (NTD) to different degrees. A, Glutathione S-transferase (GST) fusions of clathrin-binding peptides used in this study. Clathrin-box motifs (CBMs) are aligned in bold. Amph4T1, human amphiphysin I CBM plus additional residues derived from the expression vector²²; AmphCBM, human amphiphysin I CBM; AP2CBM, CBM from flexible hinge of $\beta 2$ adaptin subunit of human AP2; HDAg-L1, putative CBM from clade I hepatitis D virus large antigen; HDAg-L2, putative CBM from clade II hepatitis D virus large antigen; Wbox, human amphiphysin W box binding motif. B, Capture ("GST pull-down") of purified clathrin by GST-tagged clathrin-binding peptides. Clathrin (input) was incubated with glutathione sepharose pre-loaded with GST-tagged "bait" proteins. After washing, proteins bound to the beads (pellet) were subjected to SDS-PAGE and immunoblotting (WB) using an antibody that recognizes clathrin NTD (α NTD). C, Capture of His-NTD-NEMO by GST-tagged clathrin binding peptides. Purified recombinant His-NTD-NEMO was used in GST pull-down experiments as in (B).

was not significantly captured by GST alone (Figure 1B). Interestingly, clathrin was not efficiently captured by GST fused to either of the HDAg-L C-terminal extensions tested (Figure 1B).

To facilitate subsequent mutational work the N-terminal domain (NTD) of bovine clathrin heavy chain (100% amino acid identity to human clathrin heavy chain NTD), fused to a His₆ affinity tag at the N terminus and to the dimerization domain of NF- κ B essential modulator (NEMO)²³ at the C terminus, was purified following expression in *Escherichia coli*. This His-NTD-NEMO protein binds GST-AP2CBM much more efficiently than His-NTD lacking the NEMO oligomerization domain (Figure S1A). We ascribe this to increased avidity of binding, as His-NTD-NEMO is capable of oligomerizing at higher concentrations whereas His-NTD is monomeric (Figure S1). As observed using purified clathrin, recombinant His-NTD-NEMO is efficiently pulled-down by GST-AP2CBM, GST-AmphCBM, GST-Amph4T1 and GST-Wbox (Figure 1C). His-NTD-NEMO is weakly pulled down by GST-HDAg-L1, whereas GST-HDAg-L2 does not pull down His-NTD-NEMO any more efficiently than does GST alone.

2.2 | CBMs of cellular and viral peptides bind multiple sites on the clathrin NTD

To gain structural insight into the binding of cellular and viral peptides, recombinant NTD was crystallized in the presence of peptides corresponding to CBMs of $\beta 2$ adaptin and amphiphysin, the CBM region of the non-natural Amph4T1 sequence, and the putative CBMs of HDag-L1 and HDag-L2. These co-crystallization experiments were performed using high concentrations (3.4–3.6 mM) of clathrin-binding peptide to ensure saturation of the peptide binding sites. The structures of all co-crystals were solved and refined to high resolution (Table 1) and, surprisingly, in all cases electron density consistent with the presence of peptide bound to NTD could be observed at more than 1 locus on NTD (Figure 2).

In all the structures presented a peptide could be observed at the “clathrin box”, lying between blades 1 and 2 of the NTD β -propeller fold (“clathrin box”, Figure 2). For the cellular peptides (AP2CBM_{pep}, AmphCBM_{pep} and Amph4T1_{pep}) the binding is similar to that previously described,¹⁰ with the 3 leucine side chains of the CBM L Φ x Φ [DE] consensus sequence occupying the hydrophobic pocket formed at the groove between the 2 blades. The viral peptides (HDag-L1_{pep} and HDag-L2_{pep}) bound at a similar site on NTD. However, in both cases only 2 consecutive hydrophobic side chains could be observed in the hydrophobic pocket (“IL” and “LL” in the cases of HDag-L1_{pep} and HDag-L2_{pep}, respectively). Interestingly, for both HDag-L1_{pep} and HDag-L2_{pep} the residues bound at the clathrin box do not match predictions based on alignments to the CBM consensus sequence (Figure 1)^{16,18}: in HDag-L1_{pep} residues “ILFPA” occupy the positions corresponding to the L Φ x Φ [DE], whereas in HDag-L2_{pep} the residues “LLES”, including a C-terminal serine residue that is non-native and was added to the peptide to aid solubility, occupy the positions equivalent to the first 4 residues of the L Φ x Φ [DE] consensus.

In addition to binding at the clathrin box, we observed significant binding of the cellular peptides (AP2CBM_{pep}, AmphCBM_{pep} and Amph4T1_{pep}) at the “arrestin box”, which lies between blades 4 and 5 of the NTD β -propeller fold (“arrestin box”, Figure 2). While all 3 CBM peptides bind in the same general orientation at the arrestin box (Figure 3), the molecular details of these interactions differ from the interaction seen between NTD and the extended surface loop of the arrestin 2 long isoform (arrestin2L).¹³ Most notably, the directionality of the peptide chain is reversed. The first 2 leucine residues of each CBM (L Φ x Φ [DE]) bind in a hydrophobic cavity lined by the side chains of NTD residues W164, L183, S185, R188, V190, I194, F216, I231 and V233 plus the peptide backbones of Y184 and S191 (Figure 3B). The position occupied by these 2 peptide leucine side chains is very similar to that occupied by arrestin2L residues L338 and L335 (residues 5 and 2 of the [LI][LI]GxL arrestin box consensus motif, respectively) in the complex with NTD, despite the fact that in the arrestin2L:NTD complex the peptide backbone adopts a vastly different conformation to accommodate the 2 intervening amino acid residues (Figure 3C). In the structures presented here the side chain oxygen atom of NTD residue Q192 forms hydrogen bonds with the backbone amide protons of these 2 leucine residues (L Φ x Φ [DE]) and the side chain nitrogen atom of Q192 forms a hydrogen bond with

the carbonyl oxygen of the second leucine (L Φ x Φ [DE]). While the electron density was not sufficiently well-resolved to allow unambiguous modelling in the case of Amph4T1_{pep}, for both the AP2CBM_{pep} and AmphCBM_{pep} structures the leucine side chain of the third CBM motif residue (L Φ x Φ [DE]) occupies a similar location to the side chain of arrestin2L residue L334 ([LI][LI]GxL), binding at a hydrophobic surface patch formed by NTD residues I194, F218, H229 and I231. In the AmphCBM_{pep} structure the side chain of the phenylalanine residue that follows the CBM forms an additional hydrophobic interaction with NTD, binding in a hydrophobic cleft formed by side chains of residues H229, I231 and A247, the aryl side chain region of K245, and the peptide backbones of residues 245–247. The HDag-L2_{pep} peptide could also be observed binding at the arrestin site, although the interaction was less extensive (Figure 2). The binding was largely similar to that observed for the cellular CBM peptides: the side chains of the 2 consecutive leucine residues bound at the hydrophobic cleft and their backbone atoms interacted with the side chain of Q192 as described above. There was not strong evidence for the HDag-L1_{pep} peptide bound at the arrestin box (Figure 2).

2.3 | Structural identification of the “fourth” peptide binding site on the clathrin NTD

In addition to binding at the clathrin and arrestin boxes, in 3 of the NTD:peptide co-crystal structures solved (Amph4T1_{pep}, HDag-L1_{pep} and HDag-L2_{pep}) a bound peptide could be observed lying across the interface between blades 6 and 7 of the NTD β -propeller (Figure 2). This peptide binding site overlaps with the region identified in the functional studies of Willox and Royle¹⁴ as the fourth and final clathrin adaptor binding site on NTD, and we thus henceforth refer to it as the “Royle box” In comparison to surrounding residues, peptides were generally less well-ordered when bound at this site than when bound at the clathrin box (Table S1). However, in all cases a single orientation of the peptide could be modelled with good stereochemistry and an acceptable fit to electron density (Figure 4A).

The surface residues bound by peptides at the Royle box are highly conserved amongst eukaryotic clathrin sequences (Figure 4B). Binding at the Royle box (Figure 4C) centres on a deep hydrophobic pocket lying at the interface of blades 6 and 7, formed by the side chains of NTD residues L5, I7, F9, I282, N296 and V327. In the co-structure with Amph4T1_{pep} a phenylalanine side chain projects deep into this pocket while in the HDag-L1_{pep} and HDag-L2_{pep} structures the side chains of a leucine residue and proline residue, respectively, bind less deeply. In all structures a hydrophobic side chain (leucine in Amph4T1_{pep} and HDag-L2_{pep}, isoleucine in HDag-L1_{pep}) covers a surface hydrophobic patch formed by the hydrophobic portion of the R297 side chain and the hydrophobic faces of the peptide bonds between NTD residues 298–300 on the surface of β -propeller blade 6, and in all structures the backbone carbonyl oxygen of R297 forms a hydrogen bond with a backbone amide nitrogen of the bound peptide. In each structure 3 consecutive amino acid residues wrap around the side chain of F9 on the surface of blade 7, forming

TABLE 1 Crystallographic data collection and refinement. Values for the highest resolution shell are shown in parentheses

NTD:	AP2CBM _{pep}	AmphCBM _{pep}	Amph4T1 _{pep}	HDAg-L1 _{pep}	HDAg-L2 _{pep}
Data collection					
Space group	C222 ₁	C2	C2	C2	C2
Cell dimensions					
<i>a</i> , <i>b</i> , <i>c</i> (Å)	108.1, 133.2, 77.9	140.0, 134.1, 78.0	137.8, 131.0, 79.1	136.2, 131.2, 77.9	136.9, 131.2, 78.5
α , β , γ (°)	90.0, 90.0, 90.0	90.0, 115.1, 90.0	90.0, 116.2, 90.0	90.0, 115.6, 90.0	90.0, 115.9, 90.0
Resolution (Å)	57.1–1.8 (1.81–1.76)	67.1–1.9 (1.93–1.88)	33.6–1.7 (1.74–1.70)	48.4–2.2 (2.21–2.15)	39.2–2.0 (2.00–1.96)
<i>R</i> _{merge}	0.053 (1.538)	0.149 (1.092)	0.055 (0.751)	0.101 (0.930)	0.081 (0.581)
< <i>I</i> / σ <i>I</i> >	15.8 (1.2)	6.5 (1.3)	13.1 (1.6)	9.6 (1.5)	7.2 (1.5)
CC _{1/2}	1.000 (0.672)	0.993 (0.568)	0.999 (0.564)	0.996 (0.501)	0.996 (0.563)
Completeness (%)	100.0 (100.0)	100.0 (100.0)	98.2 (94.5)	99.7 (99.0)	94.6 (95.9)
Redundancy	7.5 (7.0)	5.1 (4.4)	3.9 (3.4)	4.5 (4.3)	2.5 (2.3)
Refinement					
Resolution (Å)	57.1–1.8 (1.81–1.76)	67.1–1.9 (1.93–1.88)	33.6–1.7 (1.74–1.70)	48.4–2.2 (2.21–2.15)	39.2–2.0 (2.01–1.96)
No. of reflections (work/free)	52,951/2740	99,868/5291	128,743/6564	63,339/3381	79,976/4224
<i>R</i> _{work} / <i>R</i> _{free}	0.176/0.205	0.204/0.234	0.158/0.185	0.175/0.207	0.169/0.193
Ramachandran favoured regions (%)	98.7	98.6	98.8	98.2	99.1
Ramachandran outliers (%)	0.0	0.0	0.0	0.0	0.0
No. of atoms					
Protein	2836	5845	5796	5634	5634
Glycerol	–	18	6	6	6
Peptide ligands	104	268	340	200	240
Water	403	803	1019	437	583
B-factors					
Protein	36.1	22.0	26.2	39.8	32.0
Glycerol	–	36.5	21.8	32.7	20.9
Peptide ligands	52.4	45.1	48.7	70.2	61.0
Water	53.5	37.8	42.3	45.6	38.2
r.m.s. deviations					
Bond lengths (Å)	0.016	0.010	0.014	0.020	0.019
Bond angles (°)	1.719	1.396	1.619	1.897	1.917
PDB ID	5M5R	5M5S	5M5T	5M5U	5M5V

Abbreviations: NTD, N-terminal domain; PDB, Protein data bank.

hydrophobic interactions with both faces of the phenylalanine residue's hydrophobic side chain benzyl group. In addition, in the co-structures with HDAg-L1_{pep} and Amph4T1_{pep} the backbone carbonyl oxygen of F9 forms a hydrogen bond with a backbone amide nitrogen of the bound peptide, and backbone atom(s) of E11 form hydrogen bond(s) with the bound peptide (1 bond in the case of HDAg-L1_{pep}, 2 in the case of Amph4T1_{pep}). Despite the similar molecular interactions made between the Royle box and the bound peptides, we note that the direction of the peptide chain differs between HDAg-L1_{pep} and Amph4T1_{pep}/HDAg-L2_{pep} (Figure 4C). In addition, unlike the binding of peptides to the clathrin and arrestin boxes, where the same side chains of the CBM sequence form key interactions, we note that residues outside the CBM consensus sequence also form extensive interactions at the Royle box.

To investigate whether the absence of AmphCBM_{pep} binding at the Royle box arose from an absence of stabilizing residues C-terminal to the CBM motif, we solved the structure of NTD in complex with a longer sequence containing the human amphiphysin I

CBM (AmphCBM_{long}_{pep}, sequence ETLDDLDFDPFK; Table S2). As observed for AmphCBM_{pep}, AmphCBM_{long}_{pep} bound NTD at the CBM and arrestin boxes but not at the Royle box (Figure S2).

2.4 | Multiple interaction sites on clathrin NTD contribute to peptide binding in vitro

A series of His-NTD-NEMO constructs with mutations at each of the 4 peptide binding sites on NTD were generated to probe whether all the interactions observed in the crystal structures contribute to binding in a biochemical context, or whether binding can be explained by a single dominant binding interaction. The mutations introduced at each site were informed by the crystal structures presented above and by previous studies (Figure 5A and Table 2). To confirm that these mutations did not introduce defects in NTD folding, the secondary structure and thermal stability of these mutants was probed by circular dichroism (CD) spectroscopy and differential scanning fluorimetry (DSF, a.k.a. Thermofluor), respectively. The CD spectra of




FIGURE 2 The clathrin-box motifs (CBMs) of cellular and viral proteins bind multiple sites on clathrin N-terminal domain (NTD). Unboxed image shows the β -propeller fold of clathrin NTD (grey ribbons) with numbers enumerating the 7 β -stranded blades. Spheres represent peptides bound at the 4 peptide-interaction sites on NTD. Boxed images show CBM-containing peptides (sticks, carbon atoms coloured as follows: AP2CBM_{pegp}, magenta; AmphCBM_{pegp}, dark green; Amph4T1_{pegp}, yellow; HDAg-L1_{pegp}, orange; HDAg-L2_{pegp}, light blue) bound at the clathrin box, arrestin box and Royle box sites on clathrin NTD (grey ribbons). Unbiased F_O-F_C electron density (3σ) used to place peptides into the structures is shown as a green mesh. Selected side chain atoms of clathrin NTD are shown (sticks with grey carbon atoms).

mutants were very similar to that of wild-type NTD (Figure S3), confirming that they had the correct secondary structure composition. However, DSF showed a number of mutants to have melting temperatures significantly lower than the wild-type protein, consistent with disrupted folding, and these mutants were thus not considered further (Figure 5B).

A selection of the correctly folded mutants was tested for ability to bind the cellular clathrin-binding motifs in GST pull-down experiments. Given the modest ability of GST-HDAg-L1 and -L2 to capture His-NTD-NEMO (Figure 1C) we limited our analysis to the cellular peptide sequences (GST-AP2CBM, GST-AmphCBM, GST-Amph4T1 and GST-Wbox). Figure 5C shows that mutations at the W box




FIGURE 3 Cellular clathrin-box motifs (CBMs) bind in a different conformation than arrestin2L at the arrestin box. A, The surface of clathrin N-terminal domain (NTD) is shown (grey) oriented as in Figure 2 (left) and rotated by 90° around the horizontal axis (right). The AmphCBM_{pep} peptide bound at the arrestin box is shown as coloured spheres. B, Close-up view of cellular CBM-containing peptides bound at the arrestin box. Peptides are shown as sticks coloured as in Figure 2. The surface of clathrin NTD is shown, coloured from high (green) to low (white) surface residue hydrophobicity, with outlines of selected surface side chains shown in grey. Bound AP2CBM_{pep} residues are numbered by their position in the LΦxΦ[DE] CBM consensus sequence. C, The extended surface loop of arrestin 2 long isoform (arrestin2L) bound at the arrestin box (PDB 3GD1).¹³ NTD is shown as in (B) and arrestin2L residues 332-340 are shown as sticks with cyan carbon atoms. Note that in (B) the direction of the bound peptides is right (N terminus) to left (C terminus), whereas in (C) the peptide chain between residues L334-L338 runs in the opposite direction.

(I154Q and I152L + I154Q) severely disrupt the ability of GST-Wbox to capture His-NTD-NEMO, consistent with previous studies.¹² His-NTD-NEMO with mutations at the clathrin box was less efficiently captured by GST-AP2CBM, the defect being most pronounced for the Q89A + F91K mutant, but capture of these mutants by GST-AmphCBM or GST-Amph4T1 was largely unperturbed (Figure 5C).

Similarly, His-NTD-NEMO mutated at the arrestin box (Q192Y) was captured less efficiently by GST-AP2CBM but the capture of this mutant by GST-AmphCBM or GST-Amph4T1 was not significantly changed (Figure 5C).

To test whether mutation at more than 1 peptide binding site further reduced capture by cellular CBM peptides, His-NTD-NEMO constructs with mutations at multiple binding loci were generated. All these 'compound mutants' had CD spectra similar to that of the wild-type protein (Figure S3) and melting temperatures within 3 K of the wild-type protein (Figure 5B), consistent with the compound mutants being well-folded. As shown in Figure 5D, while His-NTD-NEMO mutated at either the clathrin box (Q89A + F91K) or arrestin box (Q192Y) can still be captured by GST-AP2CBM, combining the mutations (Q89A + F91K + Q192Y) reduces the binding to the level of the GST control. Similarly, His-NTD-NEMO mutated at both the clathrin and arrestin boxes is captured less efficiently by GST-Amph4T1 than is the wild-type protein or protein with mutants at either site individually. The decrease in capture of His-NTD-NEMO with mutated clathrin and arrestin boxes by GST-Amph4T1 is more pronounced than is the capture of clathrin and Royle box or arrestin plus Royle box mutants. However, when NTD is mutated at all 3 sites, namely the arrestin, clathrin and Royle boxes, the extent of capture by GST-Amph4T1 is further decreased and approaches the levels seen for GST alone. GST-AmphCBM captures His-NTD-NEMO mutated at both the clathrin and arrestin boxes less efficiently than it does wild-type protein or His-NTD-NEMO with either site mutated individually. However, none of the His-NTD-NEMO mutations tested completely abolished binding to GST-AmphCBM.

2.5 | The arrestin motif of AP2 can also bind multiple sites on clathrin NTD

The hinge region of the assembly polypeptide 2 (AP2) complex β2 adaptin subunit contains 2 overlapping clathrin-binding motifs, a CBM and an arrestin-box motif (Figure 6A). However, the CBM motif can bind at the arrestin box in addition to binding at the clathrin box (Figure 2) and both such interactions contribute to NTD recruitment (Figure 5D). We therefore sought to compare the NTD binding of the β2 adaptin arrestin-box motif to that of the β2 adaptin CBM.

Two GST-tagged peptide constructs containing the arrestin-box motif of β2 adaptin (GST-AP2arrL and GST-AP2arrS) were generated (Figure 6A). Both contained the β2 adaptin arrestin-box motif (LLGDL) but, to avoid the potentially confounding issue of a carboxylate group immediately following the final residue of the motif, the sequences of their C-terminal residues differed: AP2arrS had the subsequent "L" residue of β2 adaptin appended to the arrestin-box motif, while AP2arrL had the residues "ASS" appended, corresponding to the residues that follow the LLGDL arrestin-box motif of arrestin2L.¹³ We compared the ability of GST-AP2CBM, GST-AP2arrS and GST-AP2arrL to capture either wild-type His-NTD-NEMO or a mutant (Q98A + F91K + F9W) where the clathrin and Royle boxes, but not the arrestin box, had been disrupted. Figure 6B shows that GST-AP2CBM and GST-AP2arrS capture wild-type and Q98A + F91K + F9W His-NTD-NEMO more efficiently than does AP2arrL, suggesting that the arrestin-box motif (LLGDL) alone binds the arrestin box more




FIGURE 4 Localization and characterization of the fourth peptide binding site on clathrin N-terminal domain (NTD): The Royle box. **A**, Amph4T1_{pep} (left), HDAg-L1_{pep} (middle) and HDAg-L2_{pep} (right) peptides bound at the Royle box in feature-enhanced maps²⁴ calculated using the final refined model (2 σ , magenta). For clarity, maps are shown only within 2 Å of the bound peptides. Peptides are shown as sticks, coloured as in Figure 2, and clathrin NTD is shown as a grey surface. **B**, The surface of clathrin NTD, coloured by amino acid conservation from conserved (magenta) to variable (blue), is shown oriented as in Figure 2 (left) and rotated by 90° around the vertical axis (right). The Amph4T1_{pep} peptide bound at a conserved surface patch between NTD β -propeller blades 6 and 7 (which we term the Royle box) is shown as sticks with yellow carbon atoms. **C**, Close-up view of cellular and virus peptides bound at the Royle box. Peptides are shown as sticks coloured as in Figure 2. The surface of clathrin NTD is shown, coloured from high (green) to low (white) surface residue hydrophobicity, with outlines of selected surface side chains shown in grey. A hydrophobic NTD surface pocket that is occupied by hydrophobic residues of all three peptides is marked by a dotted line. The peptide sequences used for co-crystallization are structurally aligned at the bottom of the panel. The directionality of the bound peptides is indicated. Residues that could be confidently modelled in the structures are highlighted and residues that form side chain interactions with NTD surface pockets are printed in bold type. **D**, Cellular and viral peptides bind near NTD residues functionally implicated in clathrin-mediated endocytosis. The surface of NTD (grey) is oriented as in the right image of (A) with residues mutated by Willox and Royle¹⁴ (light and dark purple) or in this study (pink) highlighted. The Amph4T1_{pep} peptide is shown as spheres. Inset shows the Amph4T1_{pep} peptide (sticks with yellow carbon atoms) bound to NTD (grey, ribbon with selected side chains shown as sticks). The carbon atoms of residues substituted in clathrin mutants that disrupt transferrin uptake,¹⁴ a proxy for clathrin-mediated endocytosis, are dark purple while those of residues where substitution does not affect transferrin uptake are light purple. The side chain of F9, mutated in this study, is coloured bright pink.

weakly than does the CBM or an extended arrestin motif (LLGDLL) containing the first 2 residues of the overlapping CBM. However, these experiments also show that GST-AP2arrL and GST-AP2arrS capture wild-type His-NTD-NEMO much more efficiently than they do the Q98A + F91K + F9W mutant, consistent with the β 2 adaptin arrestin-box motif binding to either the clathrin or Royle boxes in addition to the arrestin box.

3 | DISCUSSION

This study presents the structure of the clathrin heavy chain NTD solved in the presence of cellular and viral clathrin-binding peptides. In all cases, we observe that these peptides bind promiscuously to more than one site on the clathrin NTD surface. This differs from previous high-resolution structural characterizations of peptide binding




FIGURE 5 Mutation at single or multiple sites on clathrin N-terminal domain (NTD) disrupts binding to peptide motifs. A, Ribbon representation of NTD (grey) showing the location of residues that were mutated on their own or in combination to disrupt peptide binding at the clathrin box (blue), arrestin box (green), W box (orange) and Royle box (purple). B, Thermal stability of single- or multiple-site mutations of NTD as determined by differential scanning fluorimetry. The melting temperatures (T_M) of mutants relative to that of wild-type His-NTD are shown (error bars represent the standard deviation of measurement in triplicate). Mutations that perturb the T_M by more than 3 K (dotted line) were not considered further. C and D, Capture of NTD mutants by glutathione S-transferase (GST)-tagged clathrin-binding peptides. Purified recombinant wild-type or mutant His-NTD-NEMO was incubated with glutathione sepharose pre-loaded with GST-tagged “bait” proteins. After washing, proteins bound to the beads (pellet) were subjected to SDS-PAGE and immunoblotting (WB) using an antibody that recognizes clathrin NTD (α NTD).

TABLE 2 Clathrin heavy chain N-terminal domain mutations

Mutation	Site	Reference
Q89M	Clathrin box	25
F91A	Clathrin box	25
Q89A + F91K	Clathrin box	This study
Q192Y	Arrestin box	This study
W164E	Arrestin box	13
L183K + Q192A	Arrestin box	This study
Q152L	W box	12
I154Q	W box	12
Q152L + I154Q	W box	14
F9E	Royle box	This study
F9W	Royle box	This study
E11K	Royle box	14
Q14D + Q16M + N17S	Royle box	14

to clathrin NTD: structures of NTD solved in the presence of β 3 adaptin and β -arrestin 2 CBMs showed binding only at the clathrin box,¹⁰ only the W box site is occupied in the structure solved in the presence of a peptide derived from the “second” (PWLWLW) clathrin-binding motif of amphiphysin,¹² and the structure of NTD in complex with a long splice form arrestin 2 (arrestin2L) shows binding of 2 different peptide motifs at the clathrin and arrestin box sites. We observe that the CBMs of β 2 adaptin, amphiphysin and HDAG-L2 bind to both the clathrin and arrestin box sites. Further, we provide the first structural characterization of the putative fourth and final peptide binding site on clathrin NTD,¹⁴ which we term the Royle box.

3.1 | The arrestin box binds linear CBM peptides

The structure of arrestin2L bound to clathrin NTD revealed two different peptide epitopes bound at the clathrin and arrestin boxes.¹³




FIGURE 6 The overlapping $\beta 2$ adaptin arrestin-box and clathrin-box motifs both bind multiple sites on clathrin N-terminal domain (NTD). A, Glutathione S-transferase (GST) fusions of the clathrin-box motif (GST-AP2CBM) and arrestin-binding motif (GST-AP2arrS and GST-AP2arrL) from the hinge region of $\beta 2$ adaptin, the arrestin-box motif constructs having either the next residue of $\beta 2$ adaptin ("L", GST-AP2arrS) or the sequence that follows the LLGDLL motif of arrestin2L ("ASS", GST-AP2arrL) appended at their C termini. B, Capture of wild-type NTD or a mutant with disrupted clathrin and Royle boxes (Q89A + F91K + F9W) by GST-tagged $\beta 2$ adaptin clathrin-binding motifs. Purified recombinant wild-type or mutant His-NTD-NEMO was incubated with glutathione sepharose preloaded with GST-tagged "bait" proteins. After washing, proteins bound to the beads (pellet) were subjected to SDS-PAGE and immunoblotting (WB) using an antibody that recognizes clathrin NTD (α NTD).

The epitope bound at the arrestin box comprised an 8 amino acid surface loop that connects 2 adjacent anti-parallel beta strands of arrestin2L: this loop thus necessarily forms a relatively tight turn at its apex. The key molecular interactions are formed by three leucine side chains (L334, L335 and L338) from the arrestin2L loop that are adjacent in space (Figure 3C), but not consecutive in sequence, and biochemical studies defined the consensus binding sequence of this loop as [LI][LI]GxL.¹³

The structures presented here show that CBM peptides, matching the L Φ x Φ [DE] CBM consensus sequence, also bind NTD at the arrestin box (Figure 2) and that this interaction contributes to binding in vitro (Figure 5). Interestingly, the molecular determinants of binding are conserved between the arrestin2L loop and the CBM peptides: hydrophobic leucine or isoleucine side chains bind the groove between NTD β -propeller blades 4 and 5, occupying roughly equivalent spatial positions (Figure 3). However, the peptide backbone topology differs substantially as does the spacing between the crucial leucine/isoleucine residues. We therefore propose that the consensus sequence for binding at the arrestin box is likely to be context-dependent. In the case of arrestin2L, the amino acids that mediate binding are partly determined by the constrained nature of the surface loop. However, when presented as linear motifs, as is likely to be the biological context of the $\beta 2$ adaptin, epsin 1 and amphiphysin CBM epitopes,^{3,4,9,21,26} peptides that conform to the L Φ x Φ [DE] CBM consensus sequence can also bind the arrestin box.

Our structural characterization of CBM peptides bound promiscuously at multiple sites on clathrin NTD is largely consistent with a recent biophysical study showing promiscuous binding of long

peptides derived from $\beta 2$ adaptin and AP180 at the clathrin, arrestin and W boxes of NTD.¹⁵ However, while the long $\beta 2$ adaptin peptide used in the biophysical study harboured both CBM (LLNLD) and arrestin2L (LLGDLL) consensus sequences, the $\beta 2$ adaptin CBM (AP2CBM) peptide used here contains only a CBM. We observe that combining mutations at the arrestin and clathrin boxes completely abolishes the ability of the AP2CBM to capture NTD in GST pull-down assays, confirming that CBM peptides bind promiscuously to both sites. Unlike the previous biophysical study, peptide binding at the W box was not observed in any of the crystal structures presented here. We ascribe this to the use of much longer peptides in the biophysical study that may harbour additional, non-canonical W box binding motifs.

Given the similar molecular determinants of linear peptide binding at the clathrin and arrestin boxes, it is perhaps surprising that binding at the arrestin box was not observed in the previous co-crystallization study that used the $\beta 3$ adaptin and β -arrestin 2 CBM peptides.¹⁰ However, we note the prior study used a lower molar excess of peptide (4-fold excess versus 7- to 10-fold excess used here). Further, the extended cryo-protection protocols employed in the prior study, using cryo-preservative solutions without added peptide, may have facilitated dissociation of bound peptides from lower-affinity sites and thus removed evidence of their binding.

3.2 | Structural characterization of the Royle box

As observed at the arrestin box (above), the molecular determinants of binding at the Royle box are conserved despite a difference in peptide orientation observed for the bound HDAg-L1_{pep} peptide vs the bound HDAg-L2_{pep} and Amph4T1_{pep} peptides. However, unlike at the arrestin box, residues that form the molecular interactions at the Royle box do not correspond to those conserved in the L Φ x Φ [DE] consensus CBM sequence and we note that several peptides containing a CBM sequence (AP2CBM_{pep}, AmphCBM_{pep} and AmphCBMlong_{pep}) do not bind at the Royle box (Figures 2 and S2). Together, this suggests that a distinct consensus sequence mediates binding of cellular proteins at the Royle box. While the HDAg-L1_{pep} and HDAg-L2_{pep} peptides that bind the site occur naturally in hepatitis D virus, the Amph4T1_{pep} sequence used in this study contains amino acids corresponding to those introduced when cloning the amphiphysin CBM into the pGEX-4T1 vector.²² Attempts to define a consensus sequence and screen in silico for genuine cellular binding peptide motifs were unsuccessful due to the degeneracy of the peptide sequences bound in our structures. Identification of the Royle box consensus binding motif therefore awaits experimental elucidation.

In accordance with previous functional studies,¹⁴ all three structures of peptides bound at the Royle box presented here show binding at a conserved surface patch that lies between blades 6 and 7 of the NTD β -propeller (Figure 4B). The bound peptides all wrap around the hydrophobic side chain of NTD residue F9, which also lines the hydrophobic pocket central to the interaction of peptides at the Royle box (Figures 4C and 4D). Mutation of F9 to the bulkier residue tryptophan does not destabilize NTD (Figure 5B) but is able to diminish binding to GST-Amph4T1 when combined with mutations at the

arrestin and clathrin boxes, confirming the importance of F9 for peptide binding. Previous functional experiments showed that 2 sets of mutations at the Royle box, E11K and Q14D + Q16M + N17S (Figure 4D), were sufficient to prevent transferrin uptake (a readout for clathrin-mediated endocytosis) when combined with mutations at the clathrin, arrestin and W boxes. While the side chain of E11 does not interact directly with bound peptides, in the HDAG-L_{pep} and Amph4T1_{pep} structures E11 backbone atoms form hydrogen bonds with the bound peptide. Further, we find that the E11K mutation reduces the T_M of NTD by 3.7 K, consistent with some destabilization of the protein fold. We propose that destabilization of the local fold in the E11K NTD mutant prevents its binding to Royle box binding epitopes in cells. Residues of the second disrupting mutation, Q14D + Q16M + N17S, do not directly contact peptides bound at the Royle box in our structures but are in close proximity to peptide-binding residues (Figure 4D). Residue Q14 lies on the same short stretch of β -sheet as E11, the side chains of these two residues forming a hydrogen bond, while Q16 and N17 lie on the surface of a short α -helix immediately following Q14 (Figure 4D). The thermal stability of purified Q14D + Q16M + N17S NTD is slightly higher than the wild-type NTD (Figure 5B), which may indicate perturbation of the protein fold in the vicinity of bound peptide. Alternatively, one could speculate that the N-terminal residues of a bona fide cellular Royle box binding motif could bind the Royle box in an extended conformation and interact with these residues, although identification of such a motif remains elusive. A third set of mutations at the Royle box, N296A + R297E, did not seem to affect the ability of NTD to promote transferrin uptake,¹⁴ yet both residues are in close proximity to the peptide bound at the Royle box in the structures presented here. It is possible that the precise nature of substitutions introduced at residues N296 and R297 led to sustained transferrin uptake: N296 lines the rim of the deep hydrophobic pocket and its mutation to alanine, conferring a short hydrophobic side chain, should not prevent binding. Similarly, interactions with R297 are mediated primarily by the backbone and hydrophobic C ^{β} and C ^{γ} side chain atoms, all of which would remain when the residue was mutated to glutamate.

3.3 | HDV peptides bind the same sites on NTD as cellular peptides

Previous studies showed that GST fused to residues 198-210 of HDAG-L, comprising the majority of the HDAG-L C-terminal extension that is expressed following editing of the HDV RNA antigenome,²⁷ is capable of capturing clathrin heavy chain from cell lysates.¹⁶ Further, mutation of a putative CBM sequence in this C-terminal extension prevented both co-immunoprecipitation of clathrin heavy chain from transfected cells and the formation of virus-like particles (VLP).¹⁸ It was therefore concluded that HDAG-L is a novel viral clathrin adaptor-like protein.^{16,18} We sought to extend this observation by probing whether cellular and HDAG-L peptides bind the same or different sites on clathrin NTD, with a view to developing small-molecule inhibitors of the HDAG-L interaction with clathrin NTD that would restrict HDV replication.

Our structural results show that peptides containing the putative CBMs of two distinct HDAG-L sequences (HDAG-L1_{pep} and HDAG-L2_{pep}) bind the same sites on clathrin NTD as cellular CBM peptides, binding at the clathrin box, the Royle box and (for HDAG-L2_{pep}) the arrestin box (Figure 2). However, GST pull-down experiments performed with either purified clathrin or an oligomerized form of the NTD (His-NTD-NEMO) showed that these viral peptides capture NTD much less efficiently than do cellular CBM epitopes (Figure 1B,C). Previous cell-based studies showed that mutation of HDAG-L1 L199 to alanine severely reduced VLP production and clathrin co-immunoprecipitation.¹⁸ This is consistent with our structure, as L199 forms extensive hydrophobic contacts at both the Royle and clathrin boxes (Figure 2). HDAG-L1 mutation D203A also diminished VLP production and co-immunoprecipitation with clathrin, but in the structures presented here this residue is consistently disordered. It is thus unclear whether this mutation directly affects binding of HDAG-L to clathrin or has some secondary effect. Previous biochemical studies of HDAG-L peptides binding to purified NTD also suggested that both L199 and D203 are important for the interaction.^{16,28} However, these experiments should be viewed with caution as they utilized an extremely short NTD construct (residues 1-107) that not only lacks both the Royle and arrestin box sites but also spans only the first two blades of the NTD β -propeller and is thus highly unlikely to be correctly folded. Taken together, our results confirm that the putative CBM peptides from HDAG-L can directly bind clathrin NTD, but do so weakly. It is therefore unclear whether these viral CBM-like epitopes directly promote recruitment of clathrin heavy chain *in vivo* or whether they act synergistically with other clathrin-adaptor proteins.

3.4 | Degeneracy of clathrin-binding peptide motifs

Our structural (Figure 2) and biochemical (Figure 5) studies show that 2 distinct sequence motifs can bind the arrestin box of NTD: the arrestin-box motif ([LI][LI]GxL) and the CBM (L Φ x Φ [DE]). Further, Figure 6B shows that, when presented as linear peptides, either the β 2 adaptin CBM motif (GST-AP2CBM) or an extended arrestin-box motif (GST-AP2arrS, where the arrestin-box motif is followed by a leucine residue) bind the arrestin box more strongly than does the arrestin-box motif alone (GST-AP2arrL). This experiment also suggests that the β 2 adaptin arrestin-box motif is capable of binding the clathrin or Royle boxes (compare capture of wild-type vs Q98A + F91K + F9W His-NTD-NEMO), despite this arrestin-box motif (LLGDL) not conforming to the CBM consensus sequence. Similarly, we note that the sequences capable of binding the Royle box in crystallo are also rather degenerate, precluding the identification of a consensus binding sequence. Together, this suggests that the model of "1 consensus binding motif per peptide-binding site on clathrin NTD" might need revisiting, as the binding of these short peptides to the NTD surface is degenerate and may depend on the structural context in which the peptides are presented.

3.5 | Dynamics of association between clathrin terminal domain and adaptor peptides in coated pits

The results presented in this study underline the dynamic nature of clathrin:adaptor interactions and suggest that each clathrin terminal domain is capable of simultaneously binding multiple adaptors, even those containing only CBM (L Φ x Φ [DE]) or arrestin-box ([LI][LI]GxL) motifs. Individually, these interactions are of low affinity.^{4,15} Proteins typically bind to both specific and non-specific sites with similar association rates (k_{on}), with differential affinity conferred by differing rates of dissociation (k_{off}).²⁹ Weak bimolecular interactions in the micromolar affinity range, such as those between clathrin and its adaptors, typically correspond to dissociation rates of about 1 second or a half-time of dissociation of ~0.7 seconds.²⁹ This is significantly shorter than the timescale of productive clathrin-coated pit assembly and deformation, which occurs over the course of ~90 seconds.³⁰ Thus, we would expect adaptors to display rapid cycles of binding to and dissociation from individual binding sites on clathrin, allowing recruitment of a multitude of different adaptor molecules to any given clathrin terminal domain. It is also possible that plasticity in clathrin motif binding allows individual adaptors harbouring multiple clathrin-interaction motifs, such as epsin,²² to bind multiple sites on the clathrin N-terminal domain simultaneously, thereby increasing their apparent affinity. However, as we are not yet able to define a consensus binding sequence for the Royle box, and considering the degenerate sequence requirements for binding at the clathrin or arrestin boxes, it is unclear how frequently clathrin adaptors might be able to employ such a mode of binding.

In summary, we have shown that cellular CBM peptides bind degenerately to multiple sites on clathrin, we define a set of NTD mutations at each of the 4 peptide binding sites that do not disrupt the NTD fold, and show in biochemical assays that multiple sites contribute to binding of NTD by cellular clathrin-binding peptides. In addition, we find that viral CBM peptides bind the same sites on NTD as cellular peptides, albeit much more weakly. Finally, we present the first structural characterization of the Royle box, the fourth and final functional peptide binding site on the clathrin NTD.

4 | MATERIALS AND METHODS

4.1 | Constructs and mutagenesis

Wild-type bovine clathrin heavy chain N-terminal domain (1-363) (NTD) with an N-terminal glutathione S-transferase (GST) purification tag and thrombin cleavage site was used as described previously.¹¹ For binding assays, an oligomeric construct was designed by fusing clathrin NTD (1-363) to the NF- κ B essential modulator (NEMO) oligomerization domain (246-365) and cloning into pET-28(a) to add an N-terminal His₆ purification tag (His-NTD-NEMO). Mutated constructs encoding His-NTD-NEMO with single amino acid substitutions at residues F9, E11, Q14, Q16, N17, Q89, F91, Q152, I154, W164, L183 and Q192 were generated by QuikChange site-directed mutagenesis (Agilent) and introduction of the desired mutations was

confirmed by Sanger sequencing. Clathrin-binding motifs were cloned into pOPT3G,³¹ encoding GST followed by a human rhinovirus 3C protease cleavage site and the peptide of interest, by ligation of phosphorylated annealed oligonucleotide primers as follows: GST-HDAg-L1, residues 195-214 of hepatitis D virus large antigen (HDAg-L) clade I (UniProt POC6L6); GST-HDAg-L2, residues 194-213 of HDAg-L clade II (UniProt A4ZNG7); GST-AP2CBM, residues 629-640 of the β 2 adaptin subunit of human AP2 (UniProt P63010); GST-Wbox, residues 379-388 of human amphiphysin I (UniProt P49418); GST-AmphCBM, residues 349-358 of human amphiphysin I (UniProt P49418). Two constructs containing the arrestin-box motif (LLGDL) of the β 2 adaptin subunit of human AP2 (UniProt P63010) were generated in the same manner: GST-AP2arrS, residues 623-632 and GST-AP2arrL, residues 623-631 followed by the sequence "ASS" that corresponds to the residues C-terminal to the LLGDL arrestin-box motif of arrestin2L.¹³ An additional construct (GST-Amph4T1) encoding residues 349-356 of rat amphiphysin I (UniProt O08838; rat and human amphiphysin I residues 349-356 are identical), inserted into pGEX-4T1 after EcoRI/XhoI digestion and thus encoding 7 additional amino acids (LERPHRD) C-terminal to the amphiphysin sequence, was described previously.²²

4.2 | Protein expression and purification

A clathrin-coated vesicle fraction was isolated from pig brains essentially as described.³² Coat proteins were stripped from the vesicles³³ and clathrin was purified from the coat protein mixture by gel filtration in 0.5 M Tris pH 7.0, 1 mM DTT (Superose 6, GE Healthcare), dialyzed into 10 mM Tris pH 8.0 and stored at 4°C. All other proteins were expressed in *E. coli* strains BL21(DE3) pLysS (GST-tagged constructs) or B834(DE3) (wild-type and mutant His-NTD-NEMO). Bacteria were grown in 2 \times TY medium with appropriate selection antibiotics to an optical density (OD)₆₀₀ of 0.8-1.0, the temperature was reduced to 22°C and protein expression was induced by addition of 0.2 mM isopropyl β -D-thiogalactopyranoside. After 12-18 h cells were harvested by centrifugation (6000 \times g, 15 min, 4°C) and stored at -80°C.

Bacterial pellets containing GST-NTD were resuspended in lysis buffer (20 mM Tris pH 7.5, 200 mM NaCl, 0.05% TWEEN-20, 0.5 mM MgCl₂, 1.4 mM β -mercaptoethanol) supplemented with 200-400 U bovine DNase I (Sigma) and 200 μ L ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor cocktail (Sigma). Cells were lysed at 24 kpsi using a cell disruptor (Constant Systems) and the lysate was cleared by centrifugation (40 000g, 30 min, 4°C). Cleared lysate was incubated with glutathione Sepharose 4B (GE Healthcare) for 60 minutes at 4°C, the beads were washed (20 mM Tris pH 7.5, 200 mM NaCl, 1 mM DTT), equilibrated in thrombin cleavage buffer (20 mM Tris pH 7.5, 200 mM NaCl, 1 mM CaCl₂), and the GST tag removed by overnight incubation at room temperature with thrombin (125 U, Serva). Following incubation with fresh glutathione resin to capture liberated GST and uncleaved GST-NTD fusion, NTD was further purified using a HiLoad Superdex 200 size exclusion chromatography column (GE Healthcare) equilibrated in 10 mM Tris pH 7.5, 50 mM NaCl, 4 mM DTT. Following concentration, small aliquots (20-100 μ L) of purified NTD were

snap-frozen in liquid nitrogen and stored at -80°C .³⁴ For other GST-tagged proteins, cell pellets were resuspended in lysis buffer (20 mM HEPES pH 7.5, 300 mM NaCl, 0.05% TWEEN-20, 0.5 mM MgCl_2 , 1.4 mM β -mercaptoethanol) supplemented with DNase I and protease inhibitors as above. Cells were lysed, and lysates were clarified and incubated with glutathione resin as above. The glutathione resin was washed (20 mM HEPES pH 7.5, 300 mM NaCl, 1 mM DTT) and bound proteins were eluted using wash buffer supplemented with 25 mM reduced glutathione. Following size exclusion chromatography using HiLoad Superdex 75 or 200 columns (GE Healthcare) equilibrated in 20 mM HEPES pH 7.5, 200 mM NaCl, 1 mM DTT, fusion proteins were mixed 1:1 with 100% (v/v) glycerol and stored at -20°C .

For wild-type and mutant His-NTD-NEMO, cell pellets were resuspended in lysis buffer (20 mM Tris pH 7.5, 500 mM NaCl, 0.05% TWEEN-20, 0.5 mM MgCl_2 , 1.4 mM β -mercaptoethanol) supplemented with 2–20 mg hen egg white lysozyme (Sigma), 400 U bovine DNase I (Sigma) and 200 μL EDTA-free protease inhibitor cocktail (Sigma). The cells were lysed and the lysate clarified as described above. The cleared lysate was applied to a 1 mL HisTrap excel Ni affinity column (GE Healthcare), the column was washed (20 mM Tris pH 7.5, 500 mM NaCl, 12.5 mM imidazole pH 7.5) and the protein eluted (20 mM Tris pH 7.5, 500 mM NaCl, 250 mM imidazole pH 7.5). The Ni affinity column eluate was injected onto a HiLoad Superdex 200 column (GE Healthcare) equilibrated in 20 mM Tris pH 7.5, 200 mM NaCl, 1 mM DTT and eluted in distinct peaks, which were collected and concentrated separately to yield His-NTD-NEMO and His-NTD (Figure S1), which were both snap-frozen in liquid nitrogen as described above.

4.3 | Crystallization, data collection, structure determination and analysis

Crystals were grown at 20°C by sitting drop vapour diffusion. Clathrin NTD (1–363) was co-crystallized in complex with the following peptides (peptide sequences are listed with residues not present in the GST-tagged constructs underlined): Amph4T1_{pep} (ETLLDLDFLE); AmphCBM_{pep} (ETLLDLDFDP); AP2CBM_{pep} (CGDLLNLDLG); HDAG-L1_{pep} (SDILFPADS); HDAG-L2_{pep} (SPRLPLES); AmphCBMlong_{pep} (ETLLDLDFDPFK). Peptides were purchased from Genscript (Amph4T1_{pep}, AmphCBM_{pep} and AmphCBMlong_{pep}) or Designer Bioscience (AP2CBM_{pep}, HDAG-L1_{pep} and HDAG-L2_{pep}). All peptides were prepared as 10 mM stock solutions in 10 mM Tris pH 7.5, 50 mM NaCl, 4 mM DTT and stored at -20°C . NTD was mixed 2:1 with peptide to give final concentrations of 14 mg/mL NTD and 3.4 mM peptide for all crystallization experiments except NTD:HDAG-L2_{pep}, where 20 mg/mL NTD and 3.6 mM peptide was used. Crystals for structure determination were obtained under the following conditions (P and R indicate peptide:protein and reservoir volumes in sitting drops, respectively): NTD:Amph4T1_{pep}, 1 μL P plus 1 μL R equilibrated against a 200 μL reservoir of 1.1 M sodium malonate pH 8.0 (Hampton Research); NTD:AmphCBM_{pep}, 1 μL P plus 2 μL R equilibrated against a 200 μL reservoir of 0.85 M sodium

malonate pH 7.5; NTD:AP2CBM_{pep}, 1 μL P plus 2 μL R equilibrated against a 200 μL reservoir of 0.94 M sodium malonate pH 6.7; NTD:HDAG-L1_{pep}, 400 nL P plus 200 nL R equilibrated against a 80 μL reservoir of 1.21 M sodium malonate pH 7.0; NTD:HDAG-L2_{pep}, 200 nL P plus 400 nL R equilibrated against a 80 μL reservoir of 1.75 M sodium malonate pH 7.0; NTD:AmphCBMlong_{pep}, 1 μL P plus 2 μL R (1.04 M sodium malonate pH 7.1, 0.2 M sodium perchlorate [Jena Bioscience]) equilibrated against a 200 μL reservoir of 1.15 M sodium malonate pH 7.1. All crystals were cryoprotected by rapid transfer into a drop comprising 55% reservoir solution, 25% (v/v) glycerol and 20% (v/v) 10 mM peptide stock solution, the peptide being added to prevent dissociation from NTD of bound peptides. Crystals were then immediately flash-cooled in liquid nitrogen and stored in liquid nitrogen.

Diffraction data were recorded at 100 K on Diamond Light Source beamlines I02 (NTD:HDAG-L1_{pep}, NTD:HDAG-L2_{pep} and NTD:AmphCBMlong_{pep}) and I04-1 (NTD:Amph4T1_{pep}, NTD:AmphCBM_{pep} and NTD:AP2CBM_{pep}). Data were processed using XDS, XSCALE and Aimless (NTD:Amph4T1_{pep}, NTD:HDAG-L1_{pep} and NTD:AmphCBMlong_{pep}), or DIALS and Aimless (NTD:AmphCBM_{pep} and NTD:AP2CBM_{pep}), as implemented by the xia2 automated processing pipeline,^{35–41} or using iMOSFLM⁴² and Aimless interactively (NTD:HDAG-L2_{pep}). The structures of the NTD:HDAG-L1_{pep}, NTD:HDAG-L2_{pep}, NTD:Amph4T1_{pep}, NTD:AmphCBM_{pep} and NTD:AmphCBMlong_{pep} complexes were solved by isomorphous replacement in REFMAC5^{43,44} using a high-resolution ligand-free model of NTD (PDB 1C9I)¹⁰ as a starting model. The structure of the NTD:AP2CBM_{pep} complex was solved by molecular replacement with a single chain of NTD (PDB 1C9I, chain A) as a search model using Phaser.⁴⁵ Manual model building was performed using COOT⁴⁶ and the models were refined using REFMAC5. In all structures, the peptides were modelled after initial improvement of the peptide-free structure. The geometric quality of the models was improved by consulting the validation tools in COOT as well as the programmes MolProbity⁴⁷ and WHAT_CHECK.⁴⁸ Structure factors and final refined models have been deposited with the Protein Data Bank as listed in Table 1 and Table S2. Feature-enhanced maps, which have reduced model bias and optimized scaling to ease comparison of strong and weak features, were calculated using phenix.fem.^{24,49} Evolutionary conservation of amino acids was estimated using ConSurf⁵⁰ with default parameters and chain A of the refined NTD:Amph4T1_{pep} structure as an input model. PyMOL (Schrodinger) was used to generate molecular graphics and figures were assembled using Inkscape (<https://inkscape.org/>).

4.4 | Capture (GST pull-down) assays and immunoblotting

All steps of the clathrin or His-NTD-NEMO capture assays were performed at 4°C using a previously published protocol¹¹ adapted to enable detection of the very weak interactions investigated in this work. A total of 40 μL of glutathione sepharose 4B beads (GE Healthcare) pre-equilibrated in assay buffer (25 mM HEPES-KOH, 125 mM potassium acetate, 5 mM magnesium acetate, 2 mM

EDTA, 2 mM EGTA, 1 mM DTT, pH 7.2) were incubated for 2 h with 20 μ g (for purified clathrin pull-down experiments) or 500 μ g (for recombinant NTD pull-downs) of GST or GST fusion proteins in assay buffer to a final volume of 400 μ L. Non-immobilized bait protein was removed following centrifugation (10 000g, 2 min) and the resin was washed thrice with assay buffer. The protein-loaded resin was then incubated with 300 μ L of 0.1 mg/mL His-NTD-NEMO or His-NTD, or 0.4 μ M purified clathrin, for 2 hours. Following centrifugation, supernatants containing uncaptured protein were retained for analysis and the resins were washed 4 \times with phosphate-buffered saline. After the final wash, the resin pellet was resuspended in 80 μ L SDS-PAGE buffer and the samples were eluted by boiling for 5 min at 95°C. Input and supernatant samples were prepared in SDS-PAGE buffer. Samples (0.33% of the prey input samples, 11.25% of the eluted pellet samples, 0.6% of the supernatant kept after the prey incubation) were separated by SDS-PAGE and transferred to nitrocellulose membranes before immunoblotting using a mouse anti-clathrin N-terminal domain primary antibody (ab11221, Abcam) and fluorescently labelled goat anti-mouse secondary antibody (925-32210, LI-COR). Dried membranes were visualized using an Odyssey scanner (LI-COR).

4.5 | Biophysical assays: CD spectroscopy, differential scanning fluorimetry and multi-angle light scattering

Circular dichroism spectra were recorded on a Jasco J-810 spectropolarimeter at 20°C. Protein samples were diluted to 1 mg/mL in 50 mM phosphate buffer, pH 7.4. A total of 8 spectra per sample were recorded (50 nm/min, 1 nm bandwidth, 260–190 nm), averaged, and smoothed (Savitzky and Golay method, second order smoothing, 5 nm sliding window) using PRISM 5 (GRAPH PAD Software).

Differential scanning fluorimetry experiments to determine the melting temperature (T_M) of wild-type or mutant His-NTD were performed using a MiniOpticon real-time PCR system (BioRad) with 10 \times SYPRO Orange dye (Molecular Probes) or Viia7 real-time PCR system (Applied Biosystems) using 1 \times Protein Thermal Shift dye (Applied Biosystems). Multiple experiments confirmed that the difference between the T_M of wild-type His-NTD and mutants ($T_{M[wt]} - T_{M[mu]}$) is measured consistently using either platform. In all experiments, assay buffer (20 mM HEPES-KOH, 120 mM potassium acetate, pH 7.5) was mixed with dye stock solution and protein solution in an 8:1:1 ratio, to give 10 ng protein in a final volume of 50 μ L (MiniOpticon) or 2 ng protein in a final volume of 20 μ L (Viia7). Samples (measured in triplicate) were heated from 20°C to 90°C at 1 K/minutes (MiniOpticon) or 25 to 95°C at 1 K/20 seconds (Viia7) and fluorescence was monitored at 1 K increments. Curve fitting, melting temperature calculations and plotting were performed using MATLAB (MathWorks).

Multi-angle light scattering (MALS) experiments⁵¹ were performed at 22°C using a Superdex 200 10/300 gel filtration column (GE Healthcare) equilibrated in 20 mM Tris pH 7.5, 200 mM NaCl, 1 mM DTT. Samples (100 μ L) were injected at a flow rate of 0.5 mL/min and size exclusion was followed by inline measurement of static light scattering (DAWN 8+, Wyatt Technology) and differential

refractive index (Optilab T-rEX, Wyatt Technology). The data were analysed using Astra6 (Wyatt Technology).

ACKNOWLEDGMENTS

We thank Janet Deane for access to MALS equipment and helpful comments. We thank Diamond Light Source for access to beamlines I02 and I04-1 (mx8547 and mx11235), this access being supported in part by the EU FP7 infrastructure grant BIOSTRUCT-X (contract no. 283570). This work was supported by a Sir Henry Dale Fellowship, jointly funded by the Royal Society and the Wellcome Trust, to S.C.G. (098406/Z/12/Z), by an NIH R01 grant (GM106963; L.M.T.) and by a Wellcome grant (090909/Z/09/Z; B.T.K.). J.M. holds a Wellcome Trust studentship. CIMR is supported by a Wellcome Trust Strategic Award (079895).

The Editorial Process File is available in the online version of this article.

REFERENCES

1. Unanue ER, Ungewickell E, Branton D. The binding of clathrin triskelions to membranes from coated vesicles. *Cell*. 1981;26(3 Pt 1):439-446.
2. Kirchhausen T. Clathrin. *Annu Rev Biochem*. 2000;69:699-727.
3. Owen DJ, Collins BM, Evans PR. Adaptors for clathrin coats: structure and function. *Annu Rev Cell Dev Biol*. 2004;20:153-191.
4. Shih W, Gallusser A, Kirchhausen T. A clathrin-binding site in the hinge of the beta 2 chain of mammalian AP-2 complexes. *J Biol Chem*. 1995;270(52):31083-31090.
5. Keyel PA, Mishra SK, Roth R, Heuser JE, Watkins SC, Traub LM. A single common portal for clathrin-mediated endocytosis of distinct cargo governed by cargo-selective adaptors. *Mol Biol Cell*. 2006;17(10):4300-4317.
6. Blondeau F, Ritter B, Allaire PD, et al. Tandem MS analysis of brain clathrin-coated vesicles reveals their critical involvement in synaptic vesicle recycling. *Proc Natl Acad Sci USA*. 2004;101(11):3833-3838.
7. Borner GH, Harbour M, Hester S, Lilley KS, Robinson MS. Comparative proteomics of clathrin-coated vesicles. *J Cell Biol*. 2006;175(4):571-578.
8. Lemmon SK, Traub LM. Getting in touch with the clathrin terminal domain. *Traffic*. 2012;13(4):511-519.
9. Dell'Angelica EC, Klumperman J, Stoorvogel W, Bonifacino JS. Association of the AP-3 adaptor complex with clathrin. *Science*. 1998;280(5362):431-434.
10. ter Haar E, Harrison SC, Kirchhausen T. Peptide-in-groove interactions link target proteins to the beta-propeller of clathrin. *Proc Natl Acad Sci USA*. 2000;97(3):1096-1100.
11. Drake MT, Traub LM. Interaction of two structurally distinct sequence types with the clathrin terminal domain beta-propeller. *J Biol Chem*. 2001;276(31):28700-28709.
12. Miele AE, Watson PJ, Evans PR, Traub LM, Owen DJ. Two distinct interaction motifs in amphiphysin bind two independent sites on the clathrin terminal domain beta-propeller. *Nat Struct Mol Biol*. 2004;11(3):242-248.
13. Kang DS, Kern RC, Puthenveedu MA, von Zastrow M, Williams JC, Benovic JL. Structure of an arrestin2-clathrin complex reveals a novel clathrin binding domain that modulates receptor trafficking. *J Biol Chem*. 2009;284(43):29860-29872.
14. Willox AK, Royle SJ. Functional analysis of interaction sites on the N-terminal domain of clathrin heavy chain. *Traffic*. 2012;13(1):70-81.
15. Zhuo Y, Cano KE, Wang L, et al. Nuclear magnetic resonance structural mapping reveals promiscuous interactions between clathrin-box motif sequences and the N-terminal domain of the clathrin heavy chain. *Biochemistry*. 2015;54(16):2571-2580.

16. Huang C, Chang SC, Yu IC, Tsay YG, Chang MF. Large hepatitis delta antigen is a novel clathrin adaptor-like protein. *J Virol*. 2007;81(11):5985-5994.
17. Ivanovic T, Boulant S, Ehrlich M, et al. Recruitment of cellular clathrin to viral factories and disruption of clathrin-dependent trafficking. *Traffic*. 2011;12(9):1179-1195.
18. Huang C, Chang SC, Yang HC, Chien CL, Chang MF. Clathrin-mediated post-Golgi membrane trafficking in the morphogenesis of hepatitis delta virus. *J Virol*. 2009;83(23):12314-12324.
19. von Kleist L, Stahlschmidt W, Bulut H, et al. Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. *Cell*. 2011;146(3):471-484.
20. Slepnev VI, Ochoa GC, Butler MH, De Camilli P. Tandem arrangement of the clathrin and AP-2 binding domains in amphiphysin 1 and disruption of clathrin coat function by amphiphysin fragments comprising these sites. *J Biol Chem*. 2000;275(23):17583-17589.
21. Ramjaun AR, McPherson PS. Multiple amphiphysin II splice variants display differential clathrin binding: identification of two distinct clathrin-binding sites. *J Neurochem*. 1998;70(6):2369-2376.
22. Drake MT, Downs MA, Traub LM. Epsin binds to clathrin by associating directly with the clathrin-terminal domain. Evidence for cooperative binding through two discrete sites. *J Biol Chem*. 2000;275(9):6479-6489.
23. Ivins FJ, Montgomery MG, Smith SJ, Morris-Davies AC, Taylor IA, Rittinger K. NEMO oligomerization and its ubiquitin-binding properties. *Biochem J*. 2009;421(2):243-251.
24. Afonine PV, Moriarty NW, Mustyakimov M, et al. FEM: feature-enhanced map. *Acta Crystallogr D Biol Crystallogr*. 2015;71(Pt 3):646-666.
25. Goodman OB Jr, Krupnick JG, Gurevich VV, Benovic JL, Keen JH. Arrestin/clathrin interaction. Localization of the arrestin binding locus to the clathrin terminal domain. *J Biol Chem*. 1997;272(23):15017-15022.
26. Kalthoff C, Alves J, Urbanke C, Knorr R, Ungewickell EJ. Unusual structural organization of the endocytic proteins AP180 and epsin 1. *J Biol Chem*. 2002;277(10):8209-8216.
27. Casey JL. RNA editing in hepatitis delta virus. *Curr Top Microbiol Immunol*. 2006;307:67-89.
28. Wang YC, Huang CR, Chao M, Lo SJ. The C-terminal sequence of the large hepatitis delta antigen is variable but retains the ability to bind clathrin. *Virology*. 2009;6:31.
29. Pollard TD. A guide to simple and informative binding assays. *Mol Biol Cell*. 2010;21(23):4061-4067.
30. Loerke D, Mettlen M, Yasar D, et al. Cargo and dynamin regulate clathrin-coated pit maturation. *PLoS Biol*. 2009;7(3):e57.
31. Graham SC, Wartosch L, Gray SR, et al. Structural basis of Vps33A recruitment to the human HOPS complex by Vps16. *Proc Natl Acad Sci USA*. 2013;110(33):13345-13350.
32. Smith CJ, Grigorieff N, Pearse BM. Clathrin coats at 21 Å resolution: a cellular assembly designed to recycle multiple membrane receptors. *EMBO J*. 1998;17(17):4943-4953.
33. Pearse BM, Robinson MS. Purification and properties of 100-kD proteins from coated vesicles and their reconstitution with clathrin. *EMBO J*. 1984;3(9):1951-1957.
34. Deng J, Davies DR, Wisedchaisri G, Wu M, Hol WG, Mehlin C. An improved protocol for rapid freezing of protein samples for long-term storage. *Acta Crystallogr D Biol Crystallogr*. 2004;60(Pt 1):203-204.
35. Winter G. Xia2: an expert system for macromolecular crystallography data reduction. *J Appl Crystall*. 2009;43:186-190.
36. Kabsch W. XDS. *Acta Crystallogr D Biol Crystallogr*. 2010;66(Pt 2):125-132.
37. Evans P. Scaling and assessment of data quality. *Acta Crystallogr D Biol Crystallogr*. 2006;62(Pt 1):72-82.
38. Sauter NK, Grosse-Kunstleve RW, Adams PD. Robust indexing for automatic data collection. *J Appl Crystallogr*. 2004;37(Pt 3):399-409.
39. Zhang Z, Sauter NK, van den Bedem H, Snell G, Deacon AM. Automated diffraction image analysis and spot searching for high-throughput crystal screening. *J Appl Crystallogr*. 2006;39:112-119.
40. Collaborative Computational Project. The CCP4 suite: programs for protein crystallography. *Acta Crystallogr D Biol Crystallogr*. 1994;50(Pt 5):760-763.
41. Evans PR. An introduction to data reduction: space-group determination, scaling and intensity statistics. *Acta Crystallogr D Biol Crystallogr*. 2011;67(Pt 4):282-292.
42. Powell HR, Johnson O, Leslie AG. Autoindexing diffraction images with iMosflm. *Acta Crystallogr D Biol Crystallogr*. 2013;69(Pt 7):1195-1203.
43. Murshudov GN, Skubak P, Lebedev AA, et al. REFMAC5 for the refinement of macromolecular crystal structures. *Acta Crystallogr D Biol Crystallogr*. 2011;67(Pt 4):355-367.
44. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr D Biol Crystallogr*. 1997;53(Pt 3):240-255.
45. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. *J Appl Crystallogr*. 2007;40:658-674.
46. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. *Acta Crystallogr D Biol Crystallogr*. 2010;66(Pt 4):486-501.
47. Chen VB, Arendall WB 3rd, Headd JJ, et al. MolProbity: all-atom structure validation for macromolecular crystallography. *Acta Crystallogr D Biol Crystallogr*. 2010;66(Pt 1):12-21.
48. Hooft RW, Vriend G, Sander C, Abola EE. Errors in protein structures. *Nature*. 1996;381(6580):272.
49. Adams PD, Afonine PV, Bunkoczi G, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr*. 2010;66(Pt 2):213-221.
50. Celniker G, Nimrod G, Ashkenazy H, et al. ConSurf: using evolutionary data to raise testable hypotheses about protein function. *Isr J Chem*. 2013;53:199-206.
51. Wyatt PJ. Light-scattering and the absolute characterization of macromolecules. *Anal Chim Acta*. 1993;272(1):1-40.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Muenzner J, Traub LM, Kelly BT and Graham SC. Cellular and viral peptides bind multiple sites on the N-terminal domain of clathrin, *Traffic*, 2017;18(1):44-57.